


Controlling the Cell Stress Response to Improve Cancer Immunotherapy


Jessica E Thaxton, PhD, MsCR
Assistant Professor
Departments of Orthopedics & Microbiology & Immunology
NCI Calabresi Clinical Oncology Scholar, Hollings Cancer Center
Medical University of South Carolina




ER Stress Response Pathways

The ER is a signaling hub with the capability to define cell bioenergetic program and metabolic fate

The ER integrates external stressors with intracellular signaling cascades through sensing a burden of unfolded/misfolded proteins






The PERK Stress Response: Acute & Chronic/ Terminal Arms




Acute: Momentary attenuation of protein synthesis
Restoration of proteostasis

Chronic, Terminal Unfolded Protein Response:
Cell Death





PERK Hinders T cell anti-tumor immunity




PERK Drives a T cell Proteomic Signature of Cell Damage & Oxidative Stress Indicative of Chronic UPR






The PERK axis drives mitochondrial oxidative stress in CD8 T cells






Mitochondrial oxidative stress is associated with CD8 T cell aging and death



PD-1+ CD8 TILs experience mitochondrial oxidative stress



PERK inhibition repairs mitochondrial oxidative stress and augments α -PD-1 therapy



Summary

- 1. PERK impairs T cell anti-tumor immunity*
- 2. The terminal UPR is activated in T effector cells and is associated with oxidative stress and cell death*
- 3. PD-1+ CD8 TILs exhibit mitochondrial oxidative stress that is relieved by PERK inhibition that augments α -PD-1 therapy*

Acknowledgments

Thaxton Lab

Katie Hurst
Kiley Lawrence
Matthew Essman
Molly Sekar
Zeke Walton, MD
Lee Leddy, MD, MSCR

The authors declare no conflicts of interest
Pertaining to this work.



Collaborators & Mentorship

Zihai Li, MD, PhD
Michael Lilly, MD.
Gustavo Leone, PhD.
Chrystal Paulos, PhD
GlaxoSmithKline, Jeffrey Axten, PhD

Funding

